FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
FOLDNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus shareholders. Halper Sadeh encourages Amicus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Amicu
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
FOLDMILWAUKEE, Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional...
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
FOLDNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus shareholders. Halper Sadeh encourages Amicus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Amicu
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
FOLD(NASDAQ:FOLD) PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.
Amicus Therapeutics Announced The Publication Of A Post-hoc Analysis Of Data From The Ert-experienced Cohort Of The PROPEL Study Of Cipaglucosidase Alfa-Atga + Miglustat (Cipa+Mig) In Adults With Late-onset Pompe Disease In Muscle And Nerve
FOLDUBS Maintains Buy on Amicus Therapeutics, Raises Price Target to $22
FOLDGoldman Sachs Maintains Neutral on Amicus Therapeutics, Lowers Price Target to $9
FOLDAmicus Therapeutics Sees FY25 Revenue Growth Of 17% - 24%
FOLDAmicus Therapeutics Q1 Adj. EPS $0.03 Beats $(0.05) Estimate, Sales $125.20M Miss $135.86M Estimate
FOLDReported Earlier, Dimerix And Amicus Therapeutics Sign Exclusive U.S. License Agreement For DMX-200 In FSGS Treatment
FOLDAmicus Therapeutics Earnings Preview
FOLDWells Fargo Maintains Overweight on Amicus Therapeutics, Lowers Price Target to $17
FOLDNeedham Reiterates Hold on Amicus Therapeuticsto Hold
FOLDAmicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half
FOLDAmicus Therapeutics Q4 2024 Adj. EPS $0.09 Beats $0.01 Estimate, Sales $149.706M Beat $148.012M Estimate
FOLDCantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $21 Price Target
FOLDA Glimpse Into The Expert Outlook On Amicus Therapeutics Through 6 Analysts
FOLDNeedham Reiterates Hold on Amicus Therapeutics
FOLDReported Earlier, Amicus Reported $528M In 2024 Revenue (+32% YoY), Projects 17-24% Growth In 2025, And Highlights First Full Year Of Pombiliti + Opfolda Sales
FOLDAmicus Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue growth guidance.
FOLDAmicus Therapeutics Raises 2024 Total Revenue Growth Guidance From 26% - 31% To 30% - 32% At CER
FOLDAmicus Therapeutics Q3 2024 Adj EPS $0.10 Up From $(0.01) YoY, Sales $141.52M Beat $135.33M Estimate
FOLDMorgan Stanley Initiates Coverage On Amicus Therapeutics with Equal-Weight Rating, Announces Price Target of $14
FOLD